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Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis
Tregs suppress proliferation and
cytokine production of T effector
cells & prevent autoimmunity
Autologous Tregs
home to inflamed autoimmune livers
after infusion without side effects
Autoimmune hepatitis patients Tregs
express CXCR3 chemokine receptor
and are functional
















• Tregs from patients with autoimmune hepatitis are
suppressive, possess functional markers CD39 and
CTLA-4, and express CXCR3.
• Treg infusion in autoimmune liver disease is safe
without any side effects.
• 22-44% of infused Tregs home to and were retained
in the livers of patients with autoimmune hepatitis
for up to 72 hours.
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Background & Aims: Autoimmune hepatitis (AIH) is an immune-mediated diseasewith no curative treatment. Regulatory T cell
(Treg) therapy is potentially curative in AIH given the critical role of Tregs in preventing autoimmunity. To work effectively, adop-
tively transferred Tregs must migrate to and survive within the inflamed liver. We conducted a proof-of-concept study aiming to
assess the safety and liver-homing properties of good manufacturing practice (GMP)-grade autologous Tregs in patients with AIH.
Methods: Autologous polyclonal GMP-grade Tregs were isolated using leukapheresis and CliniMACS, labelledwith indium tropo-
lonate and re-infused intravenously to 4 patients with AIH. GMP-Treg homing to the liver was investigated with longitudinal
gammacamera and SPECT-CT scanning. GMP-Treg immunophenotype, function and immunometabolic statewere assessed during
the study.
Results: We observed that the isolated Tregs were suppressive and expressed CXCR3, a chemokine receptor involved in recruit-
ment into the inflamed liver, as well as Treg functional markers CD39, CTLA-4 and the transcription factor Foxp3. Serial gamma
camera and SPECT-CT imaging demonstrated that 22–44% of infused Tregs homed to and were retained in the livers of patients
with autoimmune hepatitis for up to 72 h. The infused cells did not localise to any off-target organs other than the spleen and bone
marrow. GMP-Tregs were metabolically competent and there were no infusion reactions or high-grade adverse effects after Treg
infusion.
Conclusion: Our novel findings suggest that the liver is a good target organ for Treg cellular therapy, supporting the development
of clinical trials to test efficacy in autoimmune hepatitis and other autoimmune liver diseases.
© 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Autoimmune hepatitis (AIH) is an immune-mediated liver dis-
ease. Its pathogenesis is poorly understood although genetic,
dietary and environmental factors have been implicated.1 It is
characterised biochemically by the presence of elevated serumami-
notransferase levels, histologically by interface hepatitis and immu-Keywords: Autoimmune hepatitis; regulatory T cells; human liver; homing; cel
therapy.
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nologically by increased levels of immunoglobulin G (IgG) in the
presence of autoantibodies.2 The condition is T cell-mediated and
occurs as a result of immune dysregulation, including dysfunctional
Tregs,3 which allow auto-reactive T cells to attack hepatocytes
resulting in lobular and interface hepatitis.3,4 There is no curative
therapy for AIH5 and most patients require life-long immunosup-
pression, putting them at risk of serious side effects.6,7If hepatic
inflammation is not controlled, persistent hepatitis progresses to
cirrhosis and liver failure. Many patients ultimately require liver
transplantation6 after which the disease can recur.
Tregs are a subset of CD4 T cells that maintain peripheral
immune homeostasis by suppressing a range of effector immune
responses to allow immune resolution and establish homeostatic
balance between immune activation and tolerance.8,9 In 1995,
Sakaguchi and colleagues showed by adoptive transfer that sub-
sets of CD4 T cells expressing the IL-2 receptor α-chain (CD25)
prevent autoimmunity by actively suppressing self-reactive lym-
phocytes.10 CD4+CD25high T cells constitute 5–10% of CD4 T cells
in the blood. Their development and function is controlled by Foxp3,
defects in which lead to autoimmune and inflammatory syndromes
in humans and mice.11 Expression of the IL-7 receptor, CD127
Box 1. Inclusion and exclusion criteria of AUTUMN patients.
Inclusion criteria
•Age ≥18 and <70 years at screening
•Diagnostic criteria for autoimmune hepatitis based on recommendations of
the International Autoimmune Hepatitis Group
•Non-cirrhotic or compensated cirrhosis
•Leukocyte count ≥4 x 109/L
•World Health Organization (WHO) performance status of 0-1
•Females of childbearing potential must have a negative pregnancy test
prior to starting study intervention
•All sexually active women of childbearing potential must agree to use a
highly effective method of contraception from the screening visit throughout
the study period and for 99 days following Treg infusion
•All sexually active males must agree to use reliable forms of contraception
during the study and the 4-month follow-up period
•Patients who can give informed consent
Exclusion criteria
• Post liver transplant or listed for liver transplantation
• Past surgical history of liver resection (including partial/hemi hepatectomy)
• Liver disease other than autoimmune related liver disease
• Positive for blood borne viruses HBV, HCV, HIV, HTLV-1, HTLV-2 or syphilis
• Evidence of other active inflammatory disease or sepsis
• Pregnancy or breastfeeding
• Poor venous access
• Decompensated cirrhosis
• Clinically significant cardiovascular disease (ischaemic heart disease, heart
failure)
• A history of any underlying previous malignancy
• Previous allergy to radio-contrast reagents
• Patients with metallic objects fitted to the body
• Any other physical or psychiatric disorder thatmay interferewith compliance,
adequate informed consent, follow up or determine the adverse events
Treg, regulatory T cell.correlates inversely with Foxp3 and Treg suppressive function;
hence Tregs are now defined as CD4+CD25highCD127lowFoxp3+
cells.12
Failure of Tregs to suppress effector cells is a typical feature of
autoimmunity, including AIH, leading to studies exploring the use
of either polyclonal13,14 or antigen-specific Tregs15–17 as cellular
therapies for autoimmune diseases. To work effectively, adoptively
transferred Tregsmust home to andmediate suppression at the tar-
get tissue. Chemokines direct the trafficking and positioning of leu-
kocytes within tissues18,19 and deficiency in CXCR3 which drives
recruitment across hepatic sinusoids3,20 has been associated with
the exacerbation of liver disease and abrogation of tolerance in
mouse models of immune-mediated hepatitis.21
In this first proof-of-concept study of Treg homing to the human
liver, we investigated the functionality and in vivo trafficking of auto-
logous, polyclonal GMP-grade Tregs in patients with AIH. We report
the cells are suppressive and metabolically competent and when
infused intravenously traffic to the liver and spleenwith little uptake
in other tissues. Thus, AIH is a good target disease for Treg therapy.
Materials and methods
Patients
Five patients with AIH (median age 39 years, range 22–64 years)
were screened. All had good peripheral venous access, met the
inclusion and exclusion criteria (Box 1) and were enrolled after
obtaining informed consent. The primary outcome was the tissue
distribution of the indium-labelled infused Tregs over 72 h fol-
lowing infusion, as assessed by serial gamma camera and SPECT-
CT imaging. Secondary outcome measures were the safety and
tolerability of Treg infusions and longitudinal changes in immu-
nophenotyping. Primary and secondary objectives and outcome
measures of the study were described in Table 1. Ethical approval
was obtained for this study (IRAS ID: 177127).
Study methodology
AUtologous T-regulatory cell tracking after InfUsion in AutoiM-
muNe Liver Disease (AUTUMN) was a single-centre, single-arm,
phase 0, feasibility pilot study, assessing the localisation of autolo-
gous GMP-grade Tregs in 4 patients with AIH. Tregs were radiola-
belled with indium, infused into patients and tracked over 72 h
using gamma and SPECT-CT scanning. Between 16th September
2016 and 11th July 2017, a total of 5 patients were recruited and
seen at the Queen Elizabeth Hospital, University Hospitals
Birmingham NHS Foundation Trust (UHB NHSFT), Birmingham,
UK. Of these, 4 completed the study. The UHB NHSFT Research &
Development (R&D) department and the East of Scotland
Research Ethics Service REC in the UK approved the study protocol
(IRAS ID: 177127). TheUniversity of Birmingham (Birmingham,UK)
acted as sponsor and the Cancer Research Clinical Trials Unit
(CRCTU), Birmingham, UK monitored the trial and provided
annual reports to the Research Ethics Committee. Ethical approval
was given by the UK National Research Ethics Service (reference
15//0135) East of Scotland Research Ethics Committee. Fig. 1 out-
lines the study design (1A) and provides a summary of the study
profile (1B).
Leukapheresis and GMP-Treg isolation
Leukocytes were obtained by a twice-blood-volume leukapher-
esis using Spectra Optia Apheresis and the mononuclear cell col-
lection protocol. GMP-grade Tregs were then isolated using
CliniMACS technology to deplete CD8 T cells and CD19 B cells andJHEP Reports 2019enrich CD4+CD25high cells (see supplementary methods). The pur-
ity of GMP Tregs was verified by flow cytometry and cells were
transferred to the radiopharmacy department and labelled with
clinical grade 111Indium tropolonate (see supplementarymethods).
Preparing 111Indium tropolonate
111Indium tropolonate was prepared from 111indium chloride
and 0.054% tropolone. The activity of the 111Indium Tropolonate
was measured in the vial on a Capintec CRC25r calibrator using
factor 216 with a copper filter. Cells for labelling were resus-
pended in 0.01% plasma in saline. The volume of indium chloride
required was calculated to provide 100 MBq and activity mea-
sured on the Capintec CRC25r using factor 216 with the copper
filter. The measured 111indium tropolonate was added drip-
wise to the cells and incubated for 20 min at room temperature,
behind lead shielding. Following incubation, cells were made up
to 15 ml with 1% plasma in saline and centrifuged at 1,000 rpm
for 5 min. Activity in the supernatant was then measured in the
Capintec CRC25r calibrator using Factor 216 with the copper
filter. This process was repeated. The labelling efficiency of the
clinical grade cells was then calculated and the volume of labelled
cells required calculated for a patient dose of up to 20 MBq.
Only 4 patients received indium tropolonate labelled Treg
infusions because cells from the first patient failed to label suffi-
ciently. The freshly labelled GMP-Tregs were then infused back
into patients via a peripheral vein on the same day.
Method for gamma camera scanning and quantitation of
uptake at 24 h in SPECT-CT
The activity of the full and used 111Indium tropolonate -In syringe
was measured on a CRC25R dose calibrator (Capintec Inc., USA)vol. 1 | 286–296 287
Table 1. Primary and secondary objectives and outcome measures. CTCAE, Common Terminology Criteria for Adverse Events; SPECT-CT, single photon
emission computed tomography; Treg, regulatory T cell.
Objectives Outcome measures
Primary Primary
To study the trafficking behaviour and tissue localisation of indium-
labelled autologous GMP-Tregs for up to 72 h after infusion.
Gamma camera imaging at 4, 24 and 72 h post Treg reinfusion to assess the kinetics of
trafficking plus SPECT-CT at 24 h to quantify tissue uptake of Treg.
Secondary Secondary
To monitor safety and tolerability of Treg infusions.
To measure immunological changes associated with Treg infusions
Adverse events and signs of toxicity were measured by CTCAE criterion/grading score
and any changes in clinical, biochemical, immunological tests
Immunological changes were assessed by longitudinal immunophenotyping and
measurement of serum cytokines and chemokines.
Research Articleusing a Thomson copper filter (Southern Scientific Ltd., UK). Ante-
rior and posterior partial body images (vertex of head to mid-
thigh) were acquired at approximately 4 ± 1 h, 24 ± 4 h and 72
± 4 h post-injection on a gamma camera (Symbia T, Siemens
USA) with medium energy general purpose collimator and scan
speed 10 cm/min. In addition, at the 24-h time point, SPECT-CT
of the same body region was performed (120 azimuths non-
circular acquisition with up to 15 s per view). SPECT images
were produced using OSEM iterative with scatter correction and
CT attenuation correction (Hybid Reconstruction, Hermes Medical
Solutions). Counts in the reconstruction SPECT images were con-
verted to activity concentrations (Bq/ml) using a calibration factor
previously obtained by scanning test objects containing known
activities of 111 indium. The reconstructed SPECT images were seg-
mented by growing volumes of interest on the reconstructed SPECT
slices or delineating organs on the CT image (Hybrid Viewer,
Hermes Medical Solutions). The activities were calculated for 7
organs of interest: liver, spleen, lungs, bone marrow (arms, leg,
spine, pelvis and head excluding brain), heart, brain and gut
(taken to be the volume of the abdomen excluding the liver, spleen
and spine). These activities were expressed as a percentage of
injected activity after correcting for radioactive decay of 111Indium.
Regions of interests (ROI)were drawnon the right liver lobe and
part of the spleen in the anterior and planarwhole body scans. Geo-
metric means of background corrected counts in the ROI for each
partial organ were calculated at the 3 time points. The geometric
mean count for each partial organ in the 24 h whole body scan
was “normalised” to the corresponding estimated activity for the
whole organ from the quantitative SPECT-CT scan. This enabled
the geometric means from the whole body scans at the 3 time
points to be converted to activities and, following decay correction,
to percentage of injected activity in the liver and spleen.
Clinical laboratory tests
Clinical, biochemical (liver enzymes, bilirubin, renal function),
immunological (IgG level, auto-antibodies) and radiology ima-
ging (Ultrasound of liver) data were collected by the NIHR Biome-
dical Research Centre research nurse and chief investigator.
Immunometabolic analysis and GMP-grade Treg suppression
of T responder cell assay
Metabolic analysiswas carried out using an Extracellular FluxAnaly-
zer XFe96 (Seahorse Bioscience). Briefly 1.0 x 105 CD4+ Tregs, CD4+
non-Tregs and CD8+ T cells were seeded onto a Cell-Tak (Corning)
coated microplate. Mitochondrial and glycolytic parameters were
measured via oxygen consumption rate (OCR) (pmoles/min) and
ECAR (mpH/min) respectively with use of real-time injections.
Cells were resuspended in XF assay media supplemented with
5.5 mM glucose and 1 mM pyruvate and injections of oligomycinJHEP Reports 2019(1 μM), carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone)
(FCCP; 1 μM) and rotenone and antimycin (both 1 μM) were used.
All chemicals were purchased from Sigma unless stated otherwise.
Calculations for individual metabolic parameters can be found as
per manufacturer’s instructions (Seahorse Bioscience).
Cytokine and chemokine analysis
Levels of cytokines, chemokines and growth factors in the periph-
eral blood were analysed by luminex on serum samples collected
on days 1, 3, 5, week 2, week 4 and week 8. One 4 ml serum-
separating tube of peripheral blood was collected at each time
point during the intervention. After being left for 1 h to settle at
room temperature the sample was centrifuged at 10,000x g for
10 min and the serum aliquoted and frozen at -80°C until the
end of the trial when all samples were analysed in parallel. Sam-
ples were analysed using the Bio-Plex ProTM Human Cytokine 27-
plex Assay, TGF-β 3-plex Assay and Th17 Cytokine IL-22 and IL-
23 sets according to manufacturer’s instructions (BioRad).
For further details regarding the materials and methods used,
please refer to the CTAT table and supplementary information.
Results
Patient characteristics
Five patientswhomet the eligibility criteria (Box 1)were enrolled to
the study. Four received a single infusion of indium tropolonate
labelled autologous, polyclonal GMP-grade Tregs andwere followed
up for 4 months. Indium labelling of the first patient’s Tregs did not
achieve the release criteria, thus no infusion was carried out*. The
mean age was 39 years, and mean disease duration was 46 months
at the time of screening. Out of 4 patients, 3 had established com-
pensated cirrhosis at the time of Treg infusion. Table 1 describe pri-
mary and secondary objectives and outcomemeasures of the study.
The demographic, biochemical, immunological and liver dis-
ease severity profile of the patients are described in Table 2A.
All patients were receiving immunosuppressive treatments
which are detailed in Table 2B.
Leukapheresis and GMP Treg isolation
Patients underwent twice-blood-volume leukapheresis at the hae-
matology day unit, Queen Elizabeth Hospital Birmingham and
Tregs were isolated from the buffy coat using a GMP-compliant pro-
tocol that we developed at the National Health Service Blood and
Transplant Unit, Birmingham. CD19+B cells and CD8+T cells were
removed then CD25+ cells enriched using a CliniMACS cell-isolator.
Between 8.9 × 106 and 86 × 106 purified CD4+CD25high Tregs were
obtained (Table 3). The freshly isolated Tregs were 92.2% Foxp3
(range: 76–96.9%) andmet the release criteria of highviability (target
≥90%, actual >98%), CD4+ percentage (≥95%), andminimal CD8 T cellvol. 1 | 286–296 288
Day 1: Leukapheresis and cell
collection
Day 2:  Autologous indium labelled
GMP Treg reinfusion
GMP-grade Treg  isolation
CD19- CD8- CD25+
selection
Label GMP-grade Tregs with
Indium tropolonate
Day 5
72 hours post infusion Gamma scan
Day 3
24 hours post infusion Gamma scan
+ SPECT CT scan
Day 2











B 5 patients assessed for eligibility




4 patients in 16 weeks follow up 
and assessment
1 patient excluded due to
failure of indium labelling to GMP-
grade Tregs
Fig. 1. Graphical representation of AUTUMN Study. (A) Schedule of activities during intervention week between days 1 and 5. (B) Study profile indicating the
number of patients to complete each stage of the study from screening, enrollment and leukapheresis to GMP-Treg infusion and 16 weeks follow-up. GMP,
Good Manufacturing Practice; Treg, regulatory T cell.(target = 1 log reduction, actual >2.5 log reduction) or CD19 B cell
contamination (target = 1 log reduction, actual >2.5 log reduction).
GMP-Treg product characteristics are described in Table 3A.
111Indium tropolonate labelling of GMP-Tregs
Freshly isolated GMP-Treg were labelled with indium tropolonate.
Table S4 reports the total number of CD4+CD25high GMP-TregsJHEP Reports 2019isolated, the amount of indium used, cell viability post indium
labelling and final radio-labelling (Mbq). Up to 20 Mbq is the
radiological safety approved limit defined by the UK’s Radioactive
Substances Advisory Committee for the infusion of indium
labelled lymphocytes for imaging. The details of indium
tropolonate labelling of GMP-Tregs prior to infusion are described
in Table 3B.vol. 1 | 286–296 289
Table 2. Patient characteristics and immunosuppressive medications taken.
Patient 1* Patient 2 Patient 3 Patient 4 Patient 5
A) Patient characteristics
Age, years 29 46 26 64 22
Gender F F M F F
Ethnicity Caucasian Caucasian African Caucasian Caucasian
ALT, IU/L 200 24 16 15 19
Creatinine, μM/L 78 63 57 58 59
IgG, g/L 22 21 15 13.3 11.7
ANA 1:1,600 Negative 1:400 1:1,600 1:400
LKM Negative Negative Negative Negative Negative
F-Actin Positive Positive Negative Negative Negative
SLA Negative Positive Negative Positive Positive
SMA Positive 1:160 1:320 1:40 1:80
UKELD 50 46 45 44 43
B) Immunosuppressive medications
Budesonide 6 mg
Prednisolone 15 mg 7.5 mg 20 mg 10 mg
Azathioprine 50 mg 100 mg 75 mg
Tacrolimus 4 mg
Mycophenolate mofetil 2 g
(A) Patients’ characteristics. Patient demographics and blood levels of ALT, creatinine, immunoglobulin G (IgG), auto-antibody profile including ANA, LKM, SLA, SMA and UKELD
scores. Patient 1* underwent leukapheresis and GMP-Treg isolation but did not receive cells due to poor labelling. (B) Immunosuppressive medications taken by the patients.
Total daily doses are shown. ALT, alanine aminotransferase; ANA, anti-nuclear antibody; LKM, anti-liver, kidney, microsomal antibody; SLA, soluble liver antigen antibody;
SMA, anti-smooth muscle antibody; Treg, regulatory T cell; UKELD, United Kingdom end-stage liver disease.
Research ArticleFunction and phenotype of GMP Tregs prior to infusion
Thegating strategy for immune cell subsetswas shown in Fig. S1. The
majority of the Tregs expressed high levels of the liver-homing che-
mokine receptor CXCR3 (Fig. 2A)(% cells: median 50%, range 20-
65%; IQR 37%) (MFI: median 200, range 95-215; IQR 94). Cells were
>95%viable (Fig. 2B), pure (Fig. 2C) and sterile as confirmedbybacter-
ial and fungal testing. GMP-grade Tregs had an effectormemoryphe-
notype (Fig. 2D) and expressed moderate to high levels of Treg
functional markers including CTLA-4 (median 64%, range 55–90%,
IQR 35%) and Foxp3 (60–90%;) (Fig. 2E). These phenotypes wereTable 3. GMP-grade Treg product characteristics and details of indium tropolo
Patient 1* Patient 2
A) GMP-grade Treg product characteristics
Total GMP-Tregs 32.9 x 106 8.9 x 10
CD8 x 106 0.01 0.019
CD20 x 106 0.006 0.044
Treg viability, % 99.53 99.7
B) Details of indium tropolonate labelling of GMP-Tregs prior to infusion
Initial activity of indium, Mbq 108 88
Post- labelled Treg viability, % 98 95
Mbq labelled GMP-Tregs, Mbq 0 6.8
(A) GMP-grade Treg product characteristics. GMP-grade Tregs frequency, purity (log redu
and viability following CliniMACS isolation. All products were negative for bacterial, fung
not reinfused as a result of poor indium labelling. (B) Details of indium tropolonate labe
as a result of poor indium labelling thus, only 4 of the 5 patients were evaluated. Once 1
and the numbers of labelled GMP-Tregs to be infused were adjusted, aiming for a dose o
being infused immediately into the same patient via a peripheral vein injection on the s
90%. Labelling efficiency was calculated by activity of indium-labelled Tregs divided by in
GMP, Good Manufacturing Practice; Treg, regulatory T cell.
JHEP Reports 2019not affected by indium labelling (Fig. S2). The Tregs suppressed T
responder cells in standard in vitro suppression assays (Fig. 2F).
Immunometabolic analysis of Tregs
We investigated whether the CD4+CD25highCD127low Tregs
from the patients were metabolically competent and thus able
to survive and function after infusion. We compared the meta-
bolic profiles of these Tregs with CD4 non-Tregs and CD8 T cell
subsets. Wemeasured the mitochondrial OCR (Fig. 3A) and extra-
cellular acidification rate (ECAR, Fig. S3A) in a Seahorsenate labelling of GMP-Tregs prior to infusion.
Patient 3 Patient 4 Patient 5







ction of CD8 and CD19 along with purity of CD4positive CD25high GMP-grade Tregs)
al and blood borne viruses (HIV, HTLV, HCV, HBV). *Treg product from patient 1 was
lling of GMP-Tregs prior to infusion. Treg product from patient 1* was not reinfused
11indium tropolonate labelling was completed, the labelling efficiency was calculated
f up to 20 Mbq. Indium-labelled GMP-Tregs were assessed for viability (>90%) before
ame day of labelling. All infused patients has indium labelling efficiency of more than
dium activity in supernatant.
vol. 1 | 286–296 290
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Fig. 2. Immunophenotype and viability of the autologous GMP-Tregs. (A) CXCR3 expression. (B) Viability post indium labelling and immediately before infusion.
(C) Purity (CD3+CD4+CD25+CD127neg Tregs expressed as percentage of total). (D) Memory/naïve phenotype showing the proportions of CD45RA+CCR7+ (naïve),
CD45RAnegCCR7+ (central memory), CD45RAnegCCR7neg (effector memory) and CD45RA+CCR7neg (tissue-resident effector memory RA-positive, TEMRA). (E)
Expressions of Treg functional surface proteins. (F) Suppressive potential. GMP, Good Manufacturing Practice; Treg, regulatory T cell.Extracellular Flux Analyzer XFe96. Injections of oligomycin (ATP
synthase inhibitor), FCCP (proton ionophore) and antimycinA/rote-
none (complex III and I inhibitors) were added to the cells in a
timed sequence. The assay revealed differences in the metabolism
of the 3 subsets. Tregs had lower basal respiration, ATP-linked
respiration and maximal respiration when compared to CD4 non-
Tregs and CD8 T cells (Fig. 3B). The spare respiratory capacity was
similar for all 3 populations (Fig. 3B) and there were no differences
in basal or maximal glycolysis levels between the 3 subsets (Fig.
S3B,C). The mitochondrial content and membrane potential of each
cell subset was measured using flow cytometry analysis of
Mitotracker® Deep Red and tetramethylrhodamine ethyl ester
(TMRE) uptake respectively. This revealed that Tregs had an
elevated mitochondrial content (Mitotracker; Fig. 3C) and functional
capacity (membrane potential) (TMRE; Fig. 3C) when compared
with CD4 non-Tregs and CD8 T cells. A subsequent analysis dividing
the cells into naïve, central memory (CM), effector memory (EM)
and tissue-resident effector memory RA (TEMRA) subsets (Fig. S3D)
showed that mitochondrial content and functional capacity were
highest in the memory cells (Fig. 3C and Fig. S3E). Since Tregs have
been shown to favour mitochondrial fatty acid oxidation as their
metabolic pathway for ATP synthesis,22,23
Homing of infused indium-labelled polyclonal Tregs
Serial gamma camera imaging was carried out at 4 h (Fig. 4Ai), 24 h
(Fig. 4Aii) and 72 h (Fig. 4Aiii) following Treg infusions. Quantification
of homing to different organs was investigated by SPECT-CT at 24 h
after Treg transfer with axial, coronal and sagittal imaging positions
(Fig. 5A). Of infused GMP-Tregs, 22–44% were detected in the liver
at 24 h with minimal localisation (1%) in the brain, lungs, heart, gut
or pelvic organs (Fig. 5B and 5C; Imaging video in supplementary
material). Bone marrow uptake varied between 9–13% and splenic
uptake between 11–24% (Fig. 5C). Individual patient Gamma camera
image scan following GMP-Treg therapy was shown in Fig. S6 and 7.JHEP Reports 2019Safety and clinical parameters
All patients underwent leukapheresis without complication. No
significant infusion-related reactions, citrate toxicity or hypoten-
sive events were observed. No grade 3 or 4 adverse events were
recordedduring the intervention and follow-upperiod. Biochemical,
Immunology, ultrasound and liver fibroscan results before and after
GMP-grade Treg infusion was described in Table S1.
Immunophenotyping post-leukapheresis and following GMP-
Treg infusion
Throughout the study and 16-week follow-up period we moni-
tored the peripheral blood immune cell profiles by multi-colour
flow cytometry. Time points of blood sampling during the study
are shown in Table S2. There were no statistically significant
changes in the frequencies of the main immune cell populations
including T cells, natural killer cells and B cells in the peripheral
blood immediately after leukaphereis and Treg infusion or
during the follow-up period. Modest changes in natural killer
T cell frequencies were observed (p = 0.047) (Figs. S4A and S6B).
A decrease in CD8 effector memory T cells was detected at
weeks 12 and 16 (p = 0.023) (Fig. 6A), whereas the other T cell
subsets were unchanged (Fig. 6A). Furthermore, we saw a
significant reduction in perforin-expressing CD8 T cells (p =
0.023) (Fig. 6B) during follow-up.
Cytokine and chemokine changes in the circulation pre and
post Treg infusion
We analysed the patients’ sera for changes in cytokines and che-
mokines before and up to 8 weeks after Treg infusion. IL-2, an
important Treg survival cytokine,24 was detected at only very
low levels. CXCL10, the ligand for CXCR3 was detectable in
blood throughout the study with no changes seen after Treg infu-
sions. No significant changes were observed in any of the inflam-
















































































































































































































































































Cell subset  p = 0.0107


























Cell subset  p = 0.0022
Naive/memory  p = 0.023
Fig. 3. Immunometabolic profile of leukapharesis Tregs. (A) OXPHOS profiles; (B) respiratory parameters including: basal respiration, maximal respiration, ATP-
linked respiration and spare respiratory capacity; (C) mitochondrial content (MitoTracker) and membrane potential (TMRE) of CD4 non-Treg, Treg and CD8 T cells
are shown. (D) Long chain fatty acid levels in normal donor (n = 4) and autoimmune diseased (n = 7) liver tissue supernatants. Statistical significance was tested by
Kruskal-Wallis test with Dunn’s multiple comparisons post-hoc test (A-B); 2-way ANOVA with Tukeys multiple comparisons post hoc test (C) and Mann-Whitney U
test with Benjamin-Hochberg correction for multiple testing. Data expressed as mean *p ≤0.05. Treg, regulatory T cell.
Research ArticleDiscussion
Deficiency or defects in Tregs have been associated with autoim-
mune liver diseases.3,7,10,20 In the Concanavalin-A murine model
of immune-mediated liver injury, adoptive transfer of ex vivo
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Fig. 4. Serial Gamma camera scanning of indium labelled GMP-Treg after infusio
post GMP-Treg infusion demonstrates the presence of indium tropolonate labelled
remained in the liver for up to 72 h (Aiii). (Anterior = Gamma camera imaging scan
view). GMP, Good Manufacturing Practice; Treg, regulatory T cell.
JHEP Reports 2019and clinical trials in autoimmune type-1 diabetes suggest the adop-
tive transfer of Tregs may be beneficial.13,14,27–29 This led us to
develop GMP-grade Tregs as a therapy for patients with AIH. How-
ever, if Treg cell therapy is to be effective in AIH, infused cells must
migrate to and be retained within the liver. Currently, little is
known about the homing of adoptively transferred Tregs in micePosterior Anterior Posterior
Aiii
maging 72 hours imaging
n. Serial Gamma camera imaging performed at 4 h (Ai), 24 h (Aii) and 72 h (Aiii)
GMP-Tregs in the liver, spleen and bone marrow. GMP-Tregs were present and
from the anterior view; posterior = Gamma camera imaging scan from posterior


















0.3 0.3 0.4 0.4
1.8 0.6 0.9 1.4
1.0 0.3 0.1 0.4
1.5 1.2 0.9 0.8















Fig. 5. SPECT-CT axial, coronal and sagittal imaging of GMP-Tregs at 24 h after infusion and cell distribution. (A) Fused images showing CT (black and white)
with functional colours overlay of SPEC-CT data. Top-bottom axial, coronal and sagittal. Moderate to intense uptake of indium labelled GMP-Tregs is shown in the
liver and the spleen. (B) Anatomical delineation of brain, heart, lungs, liver, gut and spleen on multi-planar CT. (C) Relative uptake of indium labelled GMP-Tregs in
different organs expressed as the percentage of injected activity. GMP, Good Manufacturing Practice; Treg, regulatory T cell.or humans. Thus, before embarking on clinical trials in liver disease
wewanted to determinewhere infused Tregmigrate and study fac-
tors that may determine whether they survive and function within
inflamed hepatic tissue. In total, 4 patients (3 are cirrhotic) who
were in remission underwent GMP-Treg infusion.We demonstrate
that infused Tregs home to the inflamedhuman liver and the spleen
with high levels of efficiency in patientswith AIH andwithminimal
uptake into other tissues. Our data support the development of Treg
cell therapy for treatment of AIH.
Homing of lymphocytes to inflamed tissue is guided by chemo-
kines.18,30,31 We have reported that CXCL10 is upregulated on
inflamed human sinusoids where it can act to recruit Tregs expres-
sing its receptor CXCR3.3 Consistent with this, mice lacking CXCR3
show a loss of immune tolerance and exacerbated hepatitis.21 WeJHEP Reports 2019infused the autologous Tregs intravenously into 4 patients with
AIH, 3 of whom were cirrhotic. We detected Tregs in liver tissue
at 4 h after infusion and verified their persistence in the liver for
72 h, after which the indium was no longer detectable due to
decay. More than 20% of the infused Tregs localised to the liver
and there was minimal uptake in other organs apart from the
spleen and bone marrow. This lack of homing to other tissues is
encouraging. We expected to see uptake in the lungs as the micro-
vascular pulmonary bed of the lung can trap leukocytes in some cir-
cumstances. Significant homing to the spleen was observed and
interestingly uptake by the bonemarrow, which has been reported
as a reservoir for Tregs inmice.32 One patient (patient 3, Fig. S6) had
only a rudimentary splenic remnant and in this casemore than 40%
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Fig. 6. Longitudinal changes in circulating immune cell subsets before and after leukapheresis and Treg infusion. Central memory, effectormemory and tissue-
resident effectormemoryRA-positive (TEMRA) subsets of CD8T cells, CD4non-Treg and Treg. (B)GranzymeBandperforin-expressing CD4non-Treg andCD8T cells. Each
patient’s profile between day 1 (D1) andweek 16 (W16) is illustrated by a different line: Black: Patient 2; red: Patient 3; blue: Patient 4; green: Patient 5. Significancewas
assessed using Friedman’s test with Dunn’s Multiple Comparisons post hoc analysis comparing to baseline (D1) (indicated by the box), *p ≤0.05. Treg, regulatory T cell.
Research Articlein all patients with no significant side effects. We detected high
levels of CXCR3 on the isolated Tregs, along with high levels of
CD11a and CD49d, which may explain why these cells homed effi-
ciently to the inflamed human liver where the CXCR3 ligand,
CXCL10 and the integrin ligands ICAM-1 and VCAM-1 are detected
on vessels.3,33 The cells also expressed markers critical for Treg
function such as CD39, CTLA-4 and Foxp3.
Our study was neither designed nor powered to demonstrate
efficacy, so it was not surprising that we did not see any changes
in liver enzymes, bilirubin, immunoglobulin G levels, blood cyto-
kines or fibroscan scores after the infusions (Table S5). The maxi-
mal dose we infused was 86 million cells; previous studies in
diabetes have infused up to 256 million Tregs without reported
toxicity.13 These data suggest that we can increase the number
of infused cells in future clinical trials to optimise efficacy.
We took the opportunity to look for changes in the frequencies of
circulating immune subsets after the infusions. A small but selective
and statistically significant reduction in perforin-expressing CD8
T cells is unlikely to be a consequence of simple dilution, as other
subsets were unaffected, suggesting a possible effect on effector
responses. However, this will need to be confirmed in larger studies.
An important factor in adoptive cell therapy is the ability of the
transferred cells to survive and thrive after reinfusion. In this con-
text, our findings that the Tregs have a high mitochondrial mass
and intact membrane potential is reassuring, as it suggests that
they are metabolically competent.
Tregs are dependent on IL-2 to survive and function in vivo
and we detected only very low levels of IL-2 in the blood of the
patients. Studies in autoimmune Type 1 diabetes mellitus and sys-
temic lupus erythematosus also show low circulating IL-2 levelsJHEP Reports 2019and treatmentwith lowdose IL-2 enhances CTLA-4 dependent func-
tion of Tregs isolated frompatientswithAIH via a STAT-5 dependent
mechanism.34,35 There is now increasing evidence that supplement-
ing with clinical grade low dose IL-2 enhances Treg frequency and
function.34,35 This may be particularly important in the context of
autoimmune liver disease, which is characterised by very low levels
of hepatic IL-2.20 Tregs have been shown to be functional in vitro in
the peripheral circulation,36 however they may not exert their full
functionality in the inflamed liver, as has been shown in mice.37
These observations require further investigation in future clinical
trials where the infused Tregs are retrieved from the target tissue.
Our study has several limitations. We used CD4+CD25high cells
rather than a more highly purified Treg population, which may be
obtained by, for instance, additionally selecting cells with low levels
of the IL-7 receptor, CD127.We took this approach becausewewere
concerned that further purification stepswould reduce the numbers
of cells,making radiolabelling difficult. Radiolabellingmeant thatwe
could not track infused cells after 72 h. This period was long enough
to exclude a transient trapping in the liver sinusoids but future stu-
dies, using for example deuterium labelled cells, will allow us to study
longer term tissue residency and stability.13 Ideallywewould have car-
ried out post-infusion liver biopsies to study the infused Tregs in the
livermicroenvironment.However,wedidnot think itwas ethically jus-
tified to include this in our proof-of-concept study given the risks of
liver biopsy. The purity of Tregs is defined by dementylation status,
thus epigenetic analysis with Treg-specific demethylated region
(TSDR) is important for testing the purity of Treg populations. However,
in this proof-of-concept study, we did not manipulate or expand the
Tregs.We isolated fresh Tregs and then labelled themwith indium tro-
pholonate on the sameday, thuswedid not assess the Treg puritywithvol. 1 | 286–296 294
TSDR. However, we will apply the TSDR assay to test the purity in the
next phase of the dose escalation trial.
In summary, this study demonstrates that after intravenous infu-
sion, GMP-grade Tregs show strong preferential homing to the liverJHEP Reports 2019and spleen with minimal localisation to other organs. These Tregs
also have the metabolic capacity to survive within inflamed tissues.
Thus patientswith autoimmune liver diseasesmay be excellent can-
didates for Treg therapy.Financial support
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